Clinical trials
Melanoma clinical trials
A serious form of skin cancer that develops in pigment-producing cells. We’re tracking 465 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05549297RecruitingPhase 3
Tebentafusp plus choice of treatment for advanced melanoma
This Phase 3 study compares tebentafusp treatment against the doctor’s choice of standard options in people with previously treated advanced melanoma. It aims to see which approach works better for controlling the cancer and improving outcomes.
Phoenix, ArizonaAges 18 years+ - NCT05570227Recruiting
Study metabolism in melanoma using a glucose tracer
This study looks at how melanoma cells and the body use sugar by collecting tissue samples and, for some people, giving a labeled glucose infusion. It may help researchers understand melanoma “metabolic” patterns and how they relate to cancer behavior.
Melbourne, VictoriaAges 18 years+ - NCT05649683Recruiting
Blood immune testing to predict melanoma response to immunotherapy
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
Nice, Alpes-maritimesAges 18 years+ - NCT05652673Recruiting
Stopping immunotherapy after a good melanoma response
This trial studies whether it’s safe to stop nivolumab (an immunotherapy) after your melanoma has responded well to initial treatment with ipilimumab plus nivolumab. It may help some people avoid ongoing treatment side effects while still keeping the cancer controlled.
RotterdamAges 18 years+ - NCT05673681Recruiting
Melanoma patient registry for people with skin melanoma
This is a registry that collects information from people diagnosed with an invasive skin melanoma. It may help researchers understand who gets melanoma and how it’s diagnosed and treated over time.
Badalona, BarcelonaAges Any age - NCT05704647RecruitingPhase 2
Nivolumab plus relatlimab for melanoma in the brain
This Phase 2 study tests whether nivolumab plus relatlimab can shrink or control melanoma that has spread to the brain. It may help by boosting the immune system to attack the cancer, including melanoma in brain areas that can’t be treated with prior focused radiation.
Houston, TexasAges 18 years+ - NCT05733728Recruiting
Uveal melanoma medical record study
This study looks back at past medical records of people diagnosed with uveal melanoma. It helps researchers learn about the typical course of the disease by analyzing what already happened in care.
ViennaAges 18–99 - NCT05779423RecruitingPhase 2
Freezing tumor plus two immunotherapies for advanced melanoma
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
Boston, MassachusettsAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT05856565Recruiting
AI study using skin scar images to predict anti-PD-1 response
This study tests an artificial intelligence (AI) tool that looks at images of skin “peri-scar” areas to predict how well anti-PD-1 immunotherapy will work. It may help doctors better choose treatment for people with hard-to-operate (inoperable) melanoma or certain skin cancers.
Besançon, Bourgogne-Franche-ComtéAges 18 years+ - NCT05867004Recruiting
Block TNF to boost immune response in melanoma
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
ToulouseAges 18 years+ - NCT05868707RecruitingPhase 3
Tested OH2 injection for melanoma after standard treatments fail
This Phase 3 study tests OH2 injection in people with stage III or IV melanoma that has come back or spread after at least two prior treatment types. If you qualify, you may receive OH2 injection to help shrink tumors or slow disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05878977Recruiting
Testing biomarkers in immunotherapy for advanced melanoma
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
LjubljanaAges 18 years+ - NCT05899465RecruitingPhase 3
Tranexamic acid during melanoma surgery to reduce bleeding
This Phase 3 trial tests whether giving tranexamic acid (a medicine that helps reduce bleeding) around the time of surgery can improve outcomes for people with invasive skin melanoma. It may help reduce surgical bleeding while keeping patients safe.
Aarhus, Central JutlandAges 18–80 - NCT05913388RecruitingPhase 2
Testing a new drug plus pembrolizumab versus pembrolizumab alone
This Phase 2 trial studies whether adding GB1211 to pembrolizumab works better than pembrolizumab with a placebo in people with metastatic melanoma or metastatic head and neck squamous cell cancer. It may help shrink tumors and improve outcomes, but it also carries risks from immune-based treatment.
Portland, OregonAges 18 years+ - NCT05983237RecruitingPhase 1/Phase 2
Fluzoparib, Camrelizumab, and Temozolomide for advanced melanoma
This trial tests a combination of three drugs (Fluzoparib, Camrelizumab, and Temozolomide) for people with advanced melanoma that has spread or cannot be removed by surgery. It is for those who have a specific genetic change (HR or SF3B1 mutation) and have not been treated with a PARP inhibitor before.
BeijingAges 18 years+ - NCT06008106RecruitingPhase 3
Tunlametinib pill vs chemo for advanced NRAS melanoma
This trial tests a new pill called Tunlametinib (a MEK inhibitor) compared to standard chemotherapy for people with advanced melanoma that has a specific NRAS gene change and no longer responds to immunotherapy. It aims to see if the new pill works better or is safer than chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06066138RecruitingPhase 1
Trial: Adjusting Atezolizumab Dose Based on Drug Levels in Blood
This study tests whether adjusting the dose of the immunotherapy drug atezolizumab (Tecentriq) based on its levels in your blood works well. You may be able to join if you have advanced cancer and your doctor already plans to give you this drug (alone or with other approved treatments).
Bethesda, MarylandAges 18–120 - NCT06070012RecruitingPhase 2
Tebentafusp for untreated metastatic uveal melanoma
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
Aurora, ColoradoAges 18 years+ - NCT06121180RecruitingPhase 2
Cemiplimab plus ziv-aflibercept for metastatic uveal melanoma
This trial tests two drugs, cemiplimab and ziv-aflibercept, together for people whose uveal melanoma has spread. It may be an option if previous treatments have stopped working or you haven't had treatment yet.
Los Angeles, CaliforniaAges 18 years+ - NCT06154668Recruiting
Immune cell study in melanoma patients
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
GrenobleAges 18 years+ - NCT06194929RecruitingPhase 1/Phase 2
Drug combo for melanoma that spread to the brain
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
Iowa City, IowaAges 18 years+ - NCT06216938RecruitingEarly Phase 1
RP1 virus therapy for advanced melanoma to lower lymph node spread risk
This trial tests a new kind of virus-based treatment (RP1) given directly into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. It's for people with thicker or more advanced skin melanoma that still has visible tumor or positive margins after biopsy.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06240143RecruitingPhase 1/Phase 2
Intradermal immunotherapy for high-risk stage II melanoma
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
AmsterdamAges 18 years+
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for melanoma?
- Yes. Clin2 currently lists 465 recruiting melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.